Funding for this research was provided by:
Dutch Arthritis Society (15-1-301)
China Scholarship Council (201906230308)
Received: 17 March 2021
Accepted: 3 August 2021
First Online: 19 August 2021
: The protocol has been approved by the Ethical Committee of UMC Utrecht (protocol number 02/017-E). Informed consent was obtained from all participants before the enrollment of the CHECK cohort.
: Not applicable.
: J.R reports grants from Dutch Arthritis Society, during the conduct of the study; M.K reports grants from Dutch Arthritis Association, during the conduct of the study; other from Fee for consultancy (Abbvie, Pfizer, Levicept, GlaxoSmithKline, Merck-Serono, Kiniksa, Flexion, Galapagos, CHDR) and local investigator of industry-driven trial (Abbvie), from Wolters Kluwer (UptoDate), Springer Verlag (Reumatologie en klinische immunologie), grants from Pfizer, grants from IMI-APPROACH, outside the submitted work; SB-Z reports grants from European union, Foreum, The Netherlands Organisation for Health Research and Development, Dutch Arthritis Association, CZ, personal fees from OARSI, personal fees from Pfizer, outside the submitted work.